- Home
- BELFB vs SLNO Comparison
BELFB vs SLNO Comparison
Compare BELFB & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BELFB | SLNO |
|---|---|---|
| Founded | 1949 | 1999 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | BELFB | SLNO |
|---|---|---|
| Price | $221.75 | $38.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $164.75 | $112.70 |
| AVG Volume (30 Days) | 159.8K | ★ 1.3M |
| Earning Date | 01-01-0001 | 04-16-2026 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,450,788.00 |
| Revenue This Year | $28.52 | N/A |
| Revenue Next Year | $6.49 | $158.06 |
| P/E Ratio | $42.80 | ★ N/A |
| Revenue Growth | N/A | ★ 138.82 |
| 52 Week Low | $58.00 | $36.67 |
| 52 Week High | $248.61 | $89.12 |
Technical Indicators
Market Signals| Indicator | BELFB | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 56.86 | 39.60 |
| Support Level | $224.57 | $36.67 |
| Resistance Level | $248.61 | $41.84 |
| Average True Range (ATR) | 13.44 | 2.20 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 43.91 | 22.03 |
Price Performance
Historical ComparisonAbout BELFB Bel Fuse Inc. Class B
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.